Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Camlin Fine Sciences Ltd Regulatory Filings 2021

Oct 1, 2021

59255_rns_2021-10-01_e8ceda64-dcfd-491c-9a6c-b5d8989d7a34.pdf

Regulatory Filings

Open in viewer

Opens in your device viewer

==> picture [100 x 31] intentionally omitted <==

1[st] October, 2021

||To,BSE Limited,25, P. J. Towers,Dalal Street,Mumbai – 400 001**Ref:**CompanyScripCode: 532834|To,Listing Department,National Stock Exchange of India Ltd.,Exchange Plaza, Bandra Kurla Complex,Bandra (East), Mumbai‐ 400051**Ref:Symbol:**CAMLINFINE||Series: EQ| |---|---|---|

Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ‐ (“SEBI LODR”)

Achievement of 100% capacity utilisation for the month of September 2021 at the Company’s Diphenol manufacturing plant situated at Dahej, Gujarat

Dear Sirs,

We wish to inform you that the company has successfully achieved 100% capacity utilisation for the month of September 2021 at its Diphenol manufacturing plant at Dahej SEZ, District Bharuch, Gujarat.

Kindly take the above information on records.

Thanking You, For Camlin Fine Sciences Limited Santosh Parab Chief Financial Officer

==> picture [426 x 57] intentionally omitted <==